Google DeepMind Chairman Demis Hassabis outlines how cutting-edge AI models are transforming physical sciences, moving beyond digital text generation into biological and molecular simulation. Hassabis emphasizes that spin-off venture Isomorphic Labs is accelerating drug discovery by utilizing AlphaFold-inspired architectures to predict complex molecular interactions. The interview highlights DeepMind’s ongoing strategic focus on merging reinforcement learning with deep neural networks to tackle complex, multi-step real-world reasoning tasks. While acknowledging rapid advancements toward artificial general intelligence (AGI), Hassabis stresses the absolute necessity of rigorous safety frameworks and empirical testing. The discussion reflects Alphabet’s broader ambition to translate fundamental AI breakthroughs into tangible commercial applications across healthcare, therapeutics, and enterprise technology.

Full interview : Google DeepMind Chairman, Demis Hassabis answers questions on how artificial intelligence is revolutionizing biology, drug design, and the path toward general intelligence.